The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine
Abstract
Engineering nanomaterials are increasingly considered promising and powerful biomedical tools or devices for imaging, drug delivery, and cancer therapies, but few nanomaterials have been tested in clinical trials. This wide gap between bench discoveries and clinical application is mainly due to the limited understanding of the biological identity of nanomaterials. When they are exposed to the human body, nanoparticles inevitably interact with bodily fluids and thereby adsorb hundreds of biomolecules. A “biomolecular corona” forms on the surface of nanomaterials and confers a new biological identity for NPs, which determines the following biological events: cellular uptake, immune response, biodistribution, clearance, and toxicity. A deep and thorough understanding of the biological effects triggered by the protein corona in vivo will speed up their translation to the clinic. To date, nearly all studies have attempted to characterize the components of protein coronas depending on different physiochemical properties of NPs. Herein, recent advances are reviewed in order to better understand the impact of the biological effects of the nanoparticle–corona on nanomedicine applications. The recent development of the impact of protein corona formation on the pharmacokinetics of nanomedicines is also highlighted. Finally, the challenges and opportunities of nanomedicine toward future clinical applications are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Albumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O'Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,350
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Lesniak, A., Fenaroli, F., Monopoli, M. P., Åberg, C., Dawson, K. A., & Salvati, A. (2012) · ACS Nano · doi:10.1021/nn300223w · Cited by 1,020
Cited by
Li, Q., Wen, C., Yang, J., Zhou, X., Zhu, Y., Zheng, J., Cheng, G., Bai, J., Xu, T., Ji, J., et al. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00344 · Cited by 790
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Qiu, M., Tang, Y., Chen, J., Muriph, R., Ye, Z., Huang, C., Evans, J., Henske, E. P., & Xu, Q. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116271119 · Cited by 504
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
Kianfar, E. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00896-3 · Cited by 471
Nanozyme for tumor therapy: Surface modification matters
Tang, G., He, J., Liu, J., Yan, X., & Fan, K. (2021) · Exploration · doi:10.1002/exp.20210005 · Cited by 441
Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies
Ding, S., Khan, A. I., Cai, X., Song, Y., Lyu, Z., Du, D., Dutta, P., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.02.001 · Cited by 440
Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment
Zhang, C., Wang, X., Du, J., Gu, Z., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202002797 · Cited by 401
A translational framework to DELIVER nanomedicines to the clinic
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01754-7 · Cited by 333
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Self-citationNanoparticle protein corona: from structure and function to therapeutic targeting
Bashiri, G., Padilla, M. S., Swingle, K. L., Shepherd, S. J., Mitchell, M. J., & Wang, K. (2023) · Lab on a Chip · doi:10.1039/d2lc00799a · Cited by 296
Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine
Ren, J., Andrikopoulos, N., Velonia, K., Tang, H., Cai, R., Ding, F., Ke, P. C., & Chen, C. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02277 · Cited by 284
Self-citationInfluencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Cao, M., Cai, R., Zhao, L., Guo, M., Wang, L., Wang, Y., Zhang, L., Wang, X., Yao, H., Xie, C., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00856-w · Cited by 271
Self-citationBioactive inorganic nanomaterials for cancer theranostics
Pei, Z., Lei, H., & Cheng, L. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00352j · Cited by 255
The viral protein corona directs viral pathogenesis and amyloid aggregation
Ezzat, K., Pernemalm, M., Pålsson, S., Roberts, T. C., Järver, P., Dondalska, A., Bestas, B., Sobkowiak, M. J., Levänen, B., Sköld, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10192-2 · Cited by 209
Li, M., Gao, Z., Lv, H., Sekhar, K. P. C., Song, A., Jiang, X., Hao, J., & Cui, J. (2025) · ACS Nano · doi:10.1021/acsnano.5c03978 · Cited by 31
Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting
Barone, A., Zimbo, A. M., d’Avanzo, N., Tolomeo, A. M., Ruga, S., Cardamone, A., Celia, C., Scalise, M., Torella, D., La Deda, M., et al. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01378-9 · Cited by 22
Metadata
- Authors
- Cai, R., & Chen, C.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2018-12-27
- Volume
- 31
- Issue
- 45
- Pages
- e1805740-e1805740
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2907782134
- Cited by
- 589
- References
- 118
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.